AC-003 is under clinical development by Accro Bioscience Suzhou and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AC-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AC-003 is under development for the treatment of idiopathic pulmonary fibrosis (IPF), graft versus host disease (GvHD), rheumatoid arthritis, ulcerative colitis. it is administered through oral route a a capsule. It acts by targeting receptor interacting protein 1 (RIP1).
Accro Bioscience Suzhou overview
Accro Bioscience Suzhou (Accro), a subsidiary of Accro Hongkong Bioscience Co Ltd, is a biotechnology company that discovers and develops drugs for inflammatory, autoimmune and oncology diseases. It is investigating AC-003 program against idiopathic pulmonary fibrosis (IPF), graft-versus-host disease (GVHD), rheumatoid arthritis, and ulcerative colitis; AC-101 drug to treat IBD (inflammatory bowel disease) and anti-inflammatory diseases. The company is also evaluating AC-201 for psoriasis and systemic lupus erythematosus (SLE); AC-301 targeting leukemia; and RK-X for the treatment of prostrate and breast cancer. Accro focuses on molecular mechanisms of regulated cell death and related pathogenesis. It was funded by Morningside Ventures, Hongtai, Shengzhou Capital Group, and Yuanhe Holdings, among others. Accro is headquartered in Suzhou, Jiangsu, China.
For a complete picture of AC-003’s drug-specific PTSR and LoA scores, buy the report here.